AI is about to change healthcare. These 40 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Addus HomeCare, you have to believe in the long term demand for home and community based care and the company’s ability to manage reimbursement and labor pressures. The broad removal from Russell Growth indices is a market structure event that may affect trading liquidity, but it does not directly change the core near term catalyst around state reimbursement trends or the central risk from Medicare and Medicaid policy uncertainty.
The most relevant recent update here is the Q1 2026 earnings release, which showed continued profitability growth with net income of US$25.07 million and diluted EPS of US$1.36. For investors, that report helps frame how Addus is executing on its personal care and acquisition driven growth story just as index related flows and potential shareholder turnover may start to look different after the Russell changes.
Yet, while index removal might seem technical, it could still matter for those policy and reimbursement risks investors should be aware of...
Read the full narrative on Addus HomeCare (it's free!)
Addus HomeCare's narrative projects $1.7 billion revenue and $142.2 million earnings by 2029.
Uncover how Addus HomeCare's forecasts yield a $132.69 fair value, a 21% upside to its current price.
The lowest estimating analysts paint a more cautious picture, even before the index removals, with revenue only reaching about US$1.6 billion and earnings US$124.8 million by 2029, which shows how differently you and others might weigh government funding risks and possible shifts in investor demand after the Russell changes.
Explore 4 other fair value estimates on Addus HomeCare - why the stock might be worth just $111.80!
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com